Publications by authors named "Philip Hipskind"

Claim this Profile
S
SHIP1 therapeutic target enablement: Identification and evaluation of inhibitors for the treatment of late-onset Alzheimer's disease.
Cynthia D Jesudason, Emily R Mason, Shaoyou Chu, Adrian L Oblak, June Javens-Wolfe, Philip Hipskind

Alzheimers Dement (N Y)· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of β-Lactams Active against by a Consortium of Pharmaceutical Companies and Academic Institutions.
Ben Gold, Jun Zhang, Landys Lopez Quezada, Julia Roberts, Yan Ling, Philip A Hipskind

ACS Infect Dis· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Tuberculosis Drug Accelerator at year 10: what have we learned?
Bree B Aldridge, David Barros-Aguirre, Clifton E Barry, Robert H Bates, Steven J Berthel, Philip A Hipskind

Nat Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Trifluoromethyl Pyrimidinone Compounds With Activity Against .
Erik Hembre, Julie V Early, Joshua Odingo, Catherine Shelton, Olena Anoshchenko, Philip A Hipskind

Front Chem· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia.
Kristina Kesely, Panae Noomuna, Michal Vieth, Philip Hipskind, Kasturi Haldar

PLoS One· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Growth.
Peter C Ray, Margaret Huggett, Penelope A Turner, Malcolm Taylor, Laura A T Cleghorn, Philip A Hipskind

ACS Omega· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.
Anthony S Fischl, Xiaoen Wang, Beverly L Falcon, Rowena Almonte-Baldonado, Diane Bodenmiller, Philip Hipskind

Mol Cancer Ther· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis.
Julie Early, Juliane Ollinger, Crystal Darby, Torey Alling, Steven Mullen, Philip A Hipskind

ACS Infect Dis· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazopyridine Compounds Inhibit Mycobacterial Growth by Depleting ATP Levels.
Theresa O'Malley, Torey Alling, Julie V Early, Heather A Wescott, Anuradha Kumar, Philip A Hipskind

Antimicrob Agents Chemother· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Phenoxyalkylbenzimidazoles with Activity against Mycobacterium tuberculosis Appear to Target QcrB.
N Susantha Chandrasekera, Bryan J Berube, Gauri Shetye, Somsundaram Chettiar, Theresa O'Malley, Philip A Hipskind

ACS Infect Dis· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro Evaluation of Novel Nitazoxanide Derivatives against .
Joshua Odingo, Mai A Bailey, Megan Files, Julie V Early, Torey Alling, Philip A Hipskind

ACS Omega· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents.
Edison S Zuniga, Aaron Korkegian, Steven Mullen, Erik J Hembre, Paul L Ornstein, Philip A Hipskind

Bioorg Med Chem· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Evaluation of the 2-Aminothiazoles as Anti-Tubercular Agents.
Edward A Kesicki, Mai A Bailey, Yulia Ovechkina, Julie V Early, Torey Alling, Philip A Hipskind

PLoS One· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Phenoxyalkylbenzimidazoles with Antitubercular Activity.
N Susantha Chandrasekera, Torey Alling, Mai A Bailey, Megan Files, Julie V Early, Philip A Hipskind

J Med Chem· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
James R Henry, Michael D Kaufman, Sheng-Bin Peng, Yu Mi Ahn, Timothy M Caldwell, Philip A Hipskind

J Med Chem· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents.
Joshua Odingo, Theresa O'Malley, Edward A Kesicki, Torey Alling, Mai Ann Bailey, Philip A Hipskind

Bioorg Med Chem· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A high-throughput screen against pantothenate synthetase (PanC) identifies 3-biphenyl-4-cyanopyrrole-2-carboxylic acids as a new class of inhibitor with activity against Mycobacterium tuberculosis.
Anuradha Kumar, Allen Casey, Joshua Odingo, Edward A Kesicki, Garth Abrahams, Philip A Hipskind

PLoS One· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoamide channel-binding sulfonamides selectively inhibit mycobacterial lipoamide dehydrogenase.
Ruslana Bryk, Nancy Arango, Christina Maksymiuk, Anand Balakrishnan, Ying-Ta Wu, Philip Hipskind

Biochemistry· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancement of Imidazo[1,2-]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against .
Garrett C Moraski, Lowell D Markley, Jeffrey Cramer, Philip A Hipskind, Helena Boshoff

ACS Med Chem Lett· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity.
Garrett C Moraski, Lowell D Markley, Philip A Hipskind, Helena Boshoff, Sanghyun Cho

ACS Med Chem Lett· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond.
Roberto Ciccocioppo, Donald R Gehlert, Andrey Ryabinin, Simranjit Kaur, Andrea Cippitelli, Philip A Hipskind

Alcohol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala crhr1 expression following a history of dependence.
Wolfgang H Sommer, Roberto Rimondini, Anita C Hansson, Philip A Hipskind, Donald R Gehlert

Biol Psychiatry· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2,6-dimethyl-imidazo[1,2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism.
Donald R Gehlert, Andrea Cippitelli, Annika Thorsell, Anh Dzung Lê, Philip A Hipskind

J Neurosci· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of novel histamine H3 receptor antagonists.
Cynthia D Jesudason, Lisa S Beavers, Jeffrey W Cramer, Joelle Dill, Don R Finley, Philip A Hipskind

Bioorg Med Chem Lett· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acyl sulfonamide anti-proliferatives. Part 2: activity of heterocyclic sulfonamide derivatives.
Mary M Mader, Chuan Shih, Eileen Considine, Alfonso De Dios, Cora Sue Grossman, Philip A Hipskind

Bioorg Med Chem Lett· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis